Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168428 · ClinicalTrials.gov registry record · Phase 3
A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
NCT00168428: Completed Phase 3 study, sponsored by Allergan.
NCT00168428 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 705 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00168428, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
Study Summary
This is a 60 week study including a double-blind phase followed by an open-label phase.
Primary Outcome
Mean change from baseline in frequency (number) of headache days during the 28 day period ending with Week 24. Headache day defined as a calendar day \[00:00 to 23:59\] for which the patient reported \>= 4 continuous hours of headache.
Interventions
- BIOLOGICAL Botulinum Toxin Type A
- OTHER placebo (saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
What the finished NCT00168428 record still lists
NCT00168428 is an interventional study that assigns participants to a tested intervention. The registered 705 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Botulinum Toxin Type A is the first listed.
NCT00168428 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00168428 about?
NCT00168428 is a clinical study titled "A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches". This is a 60 week study including a double-blind phase followed by an open-label phase.
What is the current status of trial NCT00168428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2006-03. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00168428?
The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL), placebo (saline) (OTHER).
Who is sponsoring clinical trial NCT00168428?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00168428's enrollment target sits among peer trials
705 505th of 2000 higher than 1,495 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia